Cargando…
First line targeted therapies in breast cancer: focus on bevacizumab
The heterogeneity of metastatic breast cancer mandates the need to select therapies taking into account tumor and patient characteristics. Chemotherapy is indicated in the palliative setting especially when the disease is unresponsive to hormonal therapy or is hormone-receptor negative. The main che...
Autores principales: | Milano, Amalia, Nasti, Gugliemo, Iaffaioli, Rosario Vincenzo, Caponigro, Francesco |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721345/ https://www.ncbi.nlm.nih.gov/pubmed/19707343 |
Ejemplares similares
-
First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
por: Marchetti, Claudia, et al.
Publicado: (2019) -
First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
por: Tella, Sri Harsha, et al.
Publicado: (2022) -
FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
por: Damato, Angela, et al.
Publicado: (2021) -
Anticancer and Anti-Inflammatory Properties of Ganoderma lucidum Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment
por: Barbieri, Antonio, et al.
Publicado: (2017) -
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses
por: Brodowicz, T, et al.
Publicado: (2014)